243  Total SME IPOs listed in 2024

9485.84 Crs.  Total funds raised in 2024

219  SME IPOs listed with Gain in 2024

24  SME IPOs listed with loss in 2024

243  Total SME IPOs listed in 2024

9485.84 Crs.  Total funds raised in 2024

219  SME IPOs listed with Gain in 2024

24  SME IPOs listed with loss in 2024

243  Total SME IPOs listed in 2024

9485.84 Crs.  Total funds raised in 2024

219  SME IPOs listed with Gain in 2024

24  SME IPOs listed with loss in 2024

243  Total SME IPOs listed in 2024

9485.84 Crs.  Total funds raised in 2024

219  SME IPOs listed with Gain in 2024

24  SME IPOs listed with loss in 2024

     List of All Upcoming IPOs
Rubicon Research Limited

Mumbai

Date of DRHP : 31 Jul 2024

Issue Type : Book building Process

IPO Type :
MainBoard IPO

Rubicon Research Basic Details

   Pharmaceutical

Sub Sector: pharmaceutical formulations company

About the Company

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of six listed Indian companies assessed by F&S, and Company's Company), Rubicon Research is the only Indian pharmaceutical player with a complete focus on regulated markets. According to F&S, between Fiscals 2022 and 2024, Rubicon Research were the fastest growing Indian pharmaceuticals formulations company with a CAGR for total revenue of 62.5% which was five times higher than the average (of 11 companies, including us) assessed by F&S. According to F&S, in Fiscal 2024, Rubicon Research ranked among the top 10 Indian companies in terms of total Abbreviated New Drug Application (“ANDA”) approvals. Rubicon Research received 14 ANDA approvals from the US FDA in Fiscal 2024, 12 ANDA approvals in Fiscal 2023 and nine ANDA approvals in Fiscal 2022. According to F&S, in Fiscal 2024, among Company's 55 commercialized products (“Commercialized Products”) in the US, Rubicon Research held a market share of more than 25% by volume for seven products. Furthermore,according to F&S, none of Company's manufacturing facilities have received an “Official Action Indicated” (“OAI”) status by the US FDA since 2013.Rubicon Research believe Company's multi-disciplinary, data-driven, and return on investment (“ROI”) centric product selection framework is geared towards identifying sustainable opportunities for new product development. Rubicon Research identify and pursue such opportunities in a manner that provides them a competitive advantage by leveraging Company's development, manufacturing, and commercialization capabilities to create and grow Company's share of the market.

Financial Summary (Annualised Basis)

Revenue :
872.38 Cr.

PAT :
91.01 Cr.

Rubicon Research IPO Registrar

Link Intime India Private Limited

Rubicon Research DRHP Details

Objects of issue

  • Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by Company's Company
  • Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes

Find More IPOs

Thinking of
Listing Your Business through
SME IPO?

We can Help!

Contact Us Today

Explore Other DRHPs

Astonea Labs Limited

 SME IPO

  Chandigarh


Speciality Medicines Limited

 SME IPO

  Ahmedabad



Thinking of
Listing Your Business through
SME IPO?

We can Help!

Contact Us Today

Peer Companies Of This Sector

FAQs

Rubicon Research operates in Pharmaceutical and pharmaceutical formulations company. The Issue would be listed on MainBoard. The registrar of the Issue is Link Intime India Private Limited. The IPO type of Rubicon Research is Book building Process and Object of issue is

  • Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by Company's Company
  • Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes

The DRHP (Draft Red Herring Prospectus) of Rubicon Research IPO was filed on 31 Jul 2024.

No, Rubicon Research IPO is not yet listed. See other upcoming MainBoard IPOs here.

The IPO open date and IPO close date of Rubicon Research are not available now. You can apply in Rubicon Research IPO online using either UPI or ASBA as a payment method. ASBA IPO application can be done through net banking of your bank account. UPI IPO application is also offered by brokers, though they don't handle any banking services.

Services

IPO Advisory
IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Readiness
IPO Readiness
IPO Roadmap by improving Business Efficiencies, Financial Parameters and Corporate Structure to become IPO ready.
Fund Raising
Fund Raising
Fuelling a company's growth through Pre IPO Fund Raise, Private Equity, and Angel Investing.
SME : Business Scaling
SME Business Upscaling
Provide support to build a scalable SME business by unleashing the SME potential.
Post IPO Montoring
Post IPO Mentoring
Assisting with post IPO regulatory requirements and Performance Monitoring to achieve the milestone of Mainboard migration.

Thinking of
Listing Your Business through SME IPO?

We can help! Contact Us

Why Us?

  • Leading portal for IPOs
  • End to End Solutions
  • Known for Transparency